NSQHSS 7 Blood and blood products

Department

Personnel

7.1.1 Blood and blood product policies, procedures and/or protocols are consistent with national evidence- based guidelines for pre- transfusion practices, prescribing and clinical use of blood and blood products

7.1.2 The use of policies, procedures and/or protocols is regularly monitored

7.1.3 Action is taken to increase the safety and appropriateness of prescribing and clinically using blood and blood products

7.2.1 The risks associated with transfusion practices and clinical use of blood and blood products are regularly assessed

7.2.2 Action is taken to reduce the risks associated with transfusion practices and clinical use of blood and blood products

7.3.1 Reporting on blood and blood product incidents is included in regular incident reports

7.3.2 Adverse blood and blood product incidents are reported to and reviewed by the highest level of governance in the health service organisation

7.3.3 Health service organisations participate in relevant haemovigilance activities conducted by the organisation or at state or national level

7.4.1 Quality improvement activities are undertaken to reduce the risks of patient harm from transfusion practices and the clinical use of blood and blood products

7.5.1 A best possible history of blood product usage and relevant clinical and product information is documented in the patient clinical record

7.5.2 The patient clinical records of transfused patients are periodically reviewed to assess the proportion of records completed

7.5.3 Action is taken to increase the proportion of patient clinical records of transfused patients with a complete patient clinical record

7.6.1 Adverse reactions to blood or blood products are documented in the patient clinical record

7.6.2 Action is taken to reduce the risk of adverse events from administering blood or blood product

7.6.3 Adverse events are reported internally to the appropriate governance level and externally to the pathology service provider, blood service or product manufacturer whenever appropriate

7.7.1 Regular review of the risks associated with receipt, storage, collection and transport of blood and blood products is undertaken

7.7.2 Action is taken to reduce the risk of incidents arising from the use of blood or blood product control systems

7.8.1 Blood and blood product wastage is regularly monitored

7.8.2 Action is taken to minimise wastage of blood and blood products

7.9.1 Patient information relating to blood and blood products, including risks, benefits and alternatives, is available for distribution by the clinical workforce

7.9.2 (D) Plans for care that include the use of blood and blood products are developed in partnership with patients and carers

7.10.1 (D) Information on blood and blood products is provided to patients and carers in a format that is understood and meaningful

7.11.1 (D) Informed consent is undertaken and documented for all transfusions of blood or blood products in accordance with the informed consent policy of the health service organisation